A MedTech Company That Thinks Like a Biopharma

from The Bio Report · host Levine Media Group

Orchestra BioMed may play at the intersection of drugs and devices, but’s its business strategy is clearly drawn from the biopharmaceutical industry. The company develops its pipeline and then leverages strategic alliances with global partners who can best commercialize its products and maximize their potential. We spoke to David Hochman, CEO of Orchestra BioMed, about the company’s therapeutic devices, the large market opportunities it is targeting, and how it seeks to rewrite the way medtech companies think about partnering.

Episode metadata supplied by the publisher feed · Published Feb 13, 2020

Embed this episode

Attribution link and audio player

NOW PLAYING

A MedTech Company That Thinks Like a Biopharma

0:00 33:37

1×

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

Share this episode

Similar Episodes

No similar episodes found.

Similar Podcasts

No similar podcasts found.

Frequently Asked Questions

How long is this episode of The Bio Report?

This episode is 33 minutes long.

When was this The Bio Report episode published?

This episode was published on February 13, 2020.

Can I download this The Bio Report episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.

URL copied to clipboard!